Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Indivior    INDV   GB00BRS65X63

INDIVIOR

(INDV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/15/2020 10/16/2020 10/19/2020 10/20/2020 10/21/2020 Date
101.8(c) 105(c) 105.1(c) 104(c) 104.3 Last
1 952 937 1 563 378 800 478 813 580 274 801 Volume
-3.78% +3.14% +0.10% -1.05% +0.29% Change
More quotes
Financials (USD)
Sales 2020 584 M - -
Net income 2020 -137 M - -
Net cash position 2020 588 M - -
P/E ratio 2020 -7,23x
Yield 2020 -
Sales 2021 597 M - -
Net income 2021 47,5 M - -
Net cash position 2021 563 M - -
P/E ratio 2021 17,1x
Yield 2021 -
Capitalization 988 M 989 M -
EV / Sales 2020 0,68x
EV / Sales 2021 0,71x
Nbr of Employees 796
Free-Float 98,6%
More Financials
Company
Indivior specializes in the development, production and marketing of buprenorphine based medicines intended for the treatment of addiction to opiates. 78.6% of net sales are in the United States. 
Sector
Pharmaceuticals
Calendar
10/29 | 06:00amEarnings Release
More about the company
Notations Surperformance© of Indivior
Trading Rating : Investor Rating :
More Ratings
All news about INDIVIOR
09/30INDIVIOR : Calls for Widespread Commitment to Tackling Stigma in Patients with O..
PU
09/24INDIVIOR : Strategic Alignment Actions Announced
PU
09/24INDIVIOR : targets $70 million savings through job cuts, restructuring
RE
09/08INDIVIOR : Board Announcement
PU
09/08INDIVIOR : Board Announcement
PU
07/30INDIVIOR : second-quarter profit falls 73% as coronavirus curbs dent demand
RE
07/30INDIVIOR : Announces First Half and Second Quarter 2020 Results
PU
07/30INDIVIOR : First Half and Second Quarter 2020 Results Now Available; Conference ..
PR
07/24INDIVIOR : to pay $600 million to settle U.S. opioid treatment marketing claims
RE
07/24INDIVIOR : An Open Letter to our Stakeholders from our Interim Board Chair and C..
PU
06/30INDIVIOR : Plea Statement
PU
06/30INDIVIOR : Former Indivior CEO pleads guilty in U.S. in opioid addiction treatme..
RE
06/29INDIVIOR : appoints Mark Crossley as CEO after Shaun Thaxter steps down
RE
06/29INDIVIOR : Final June 29 Press Release CEO Appointment
PU
06/24INDIVIOR : New Data from the RECOVER™ Study Reveal Two-Year Outcomes in Pe..
PU
More news
News in other languages on INDIVIOR
08/12Addex dämmt Verlust im zweiten Quartal dank gesunkener Kosten ein
07/28Corona-Pandemie treibt Sagrotan-Hersteller Reckitt Benckiser an
07/27INDIVIOR : la menace Suboxone s'éloigne
07/27AVIS D'ANALYSTES DU JOUR : Covestro, Daimler, Epiroc, Getlink, Idorsia, Nestlé, ..
07/27Sur les marchés, la semaine pivot de l'été
More news
Chart INDIVIOR
Duration : Period :
Indivior Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INDIVIOR
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 2,79 $
Last Close Price 1,35 $
Spread / Highest target 202%
Spread / Average Target 107%
Spread / Lowest Target 55,9%
EPS Revisions
Managers
NameTitle
Mark Crossley Executive Director, CEO & COO
Daniel Tassé Chairman
Ryan Preblick CFO & Senior VP-Global Financial Planning
Christian Heidbreder Chief Scientific Officer
A. Thomas McLellan Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
INDIVIOR166.67%1 001
MERCK KGAA17.99%63 662
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD123.45%21 848
KYOWA KIRIN CO., LTD.3.03%13 727
BETTA PHARMACEUTICALS CO., LTD.63.61%6 479
YUHAN CORPORATION28.12%3 389